精华制药：获得卡左双多巴缓释片的两个药品注册证书

Core Viewpoint - Jinghua Pharmaceutical has received approval from the National Medical Products Administration for two drug registration certificates for its controlled-release capsules of carbidopa and levodopa, enhancing its product pipeline in the Parkinson's disease treatment sector [1] Group 1: Product Approval - The company is the third entity in China to obtain approval for the controlled-release capsules of carbidopa and levodopa (specification: carbidopa 50mg, levodopa 200mg) [1] - The controlled-release capsules (specification: carbidopa 25mg, levodopa 100mg) represent the first generic version in China, with the original product not registered for sale domestically [1] Group 2: Market Opportunities - The approval of the controlled-release capsules enriches the company's product offerings in the Parkinson's disease treatment field [1] - The introduction of the small specification product as the first generic in the domestic market provides the company with additional business opportunities in this niche market [1]